Marth C. Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial:  . CBN [Internet]. 2017 Aug. 17 [cited 2025 Apr. 15];5(2):3-4. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/177